Results 151 to 160 of about 41,281 (176)

Ritonavir

Reactions Weekly, 2016
  +4 more sources

Ritonavir

Reactions Weekly, 2002
openaire   +1 more source

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Lancet, The, 2020
Peter Horby, Marion Mafham, Natalie Staplin   +2 more
exaly  

Ritonavir

Reactions Weekly, 2005
openaire   +1 more source

Ritonavir

Reactions Weekly, 2017
  +4 more sources

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Lancet, The, 2006
Joseph J Eron, Patrick Yeni, Vicente Estrada   +2 more
exaly  

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Lancet, The, 2008
Jean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarría   +2 more
exaly  

Ritonavir and Lopinavir/Ritonavir

2007
openaire   +1 more source

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

Lancet, The, 2007
JOSÉ Valdez Madruga, Daniel Berger, Fredy Suter   +2 more
exaly  

Nirmatrelvir and ritonavir

Clinical Therapeutics
openaire   +2 more sources